The UK’s National Institute for Health and Care Excellence (NICE) has updated its advice on the treatment of low back pain in those over 16, recommending exercise in all forms as the best way to begin management. The guidelines now refer to treatment for sciatica as well as back pain.
The International Society for the Advancement of Spine Surgery (ISASS) has issued a policy statement recommending the coverage of lumbar decompression with interlaminar stabilisation in carefully selected patients.
Junyoung Ahn (Department of Orthopedic Surgery, Rush University Medical Center, Chicago, USA) and others report in The Spine Journal that continued surgical experience in the context of minimally invasive lumbar decompression, with or without discectomy, is associated with reduced operative times and reduced hospital stay, but not improved clinical outcomes. They conclude that a minimally invasive lumbar decompression could, therefore, be performed safely without prior experience.
The Solitaire™ Platinum Revascularization Device is the next generation into the Solitaire™ family which has an enhanced meaningful visibility that provides feedback during placement, deployment and retrieval in the treatment of stroke patients, completing Medtronic’s stroke portfolio with the longest and widest stent retriever available in the market with its new 6x40mm stent.
Enrolment is now complete in the ARISE II clinical trial which is assessing the safety and effectiveness of the EmboTrap II revascularisation device (Neuravi), an advanced stent retriever platform for the treatment of acute ischaemic stroke.
As principal investigator for the REVASCAT and DAWN trials and having leadership roles in the SWIFT PRIME and ESCAPE trials, Tudor Jovin (University of Pittsburgh School of Medicine, Pittsburgh, USA) has been heavily involved in the development of the field of stroke treatment for many years. In this interview with NeuroNews, he discusses the development of his career, the urgent updates that need to be made in the stroke treatment strategy and gives his advice for young interventional neurologists.
As the number of patients eligible for endovascular treatment of acute ischaemic stroke increases, centres across Europe must consider whether there are enough interventionalists to fight the burden of stroke. According to Urs Fischer (University of Bern, Bern, Switzerland), while some countries, like Germany, might have an adequate number of interventionalists capable of providing thrombectomy procedures, the rest of Europe does not.
The primary results of the ASTER randomised controlled trial (RCT) have shown no statistically significant difference between ADAPT (a direct aspiration first pass technique) and stent retriever as frontline mechanical thrombectomy strategies in the treatment of large vessel occlusion (LVO) stroke.
Endovascular aneurysm therapy today is characterised by a rapidly growing and evolving collection of available treatment devices. The challenge in achieving optimal results lies not only in the manual skill of an individual operator, but certainly also in selecting the best treatment approach for a given patient’s aneurysm.
In 2010, it was reported that the world-wide prevalence of individuals living with a stroke was approximately 33 million, with 17 million new strokes occurring every year. Additionally, it is estimated that 87% of these strokes are designated ischaemic strokes, with 30–40% having no identifiable aetiology on initial evaluation. For this reason, these strokes receive the designation of cryptogenic strokes or embolic strokes of undetermined source (ESUS).
Female athletes are 50% more likely than male athletes to have a sports-related concussion, according to a preliminary study released to be presented at the American Academy of Neurology’s 69th Annual Meeting (ANN; Boston, USA, April 22-28, 2017).
Stroke patients receiving clot-busting medications before arriving at the hospital have a lower risk for disability afterward, according to research presented at the American Stroke Association’s International Stroke Conference 2017 (ISC; 22–24 February, Houston, USA).
People who survive brain bleeds are at significantly higher risk of later developing depression and dementia, according to research presented at the American Stroke Association’s International Stroke Conference 2017 (ISC; 22–24 February, Houston, USA).
A new study published online by JAMA Neurology examines the long-term outcomes of patients with aggressive forms of multiple sclerosis who failed to respond to standard therapies and who underwent autologous hematopoietic stem cell transplantation using their own stem cells.
The latest study on hormone therapy and Alzheimer’s disease shows no relationship between taking the drugs and developing the disease years later. Some previous studies have shown that hormone therapy may increase the risk of the disease, while others have shown that it may reduce the risk. The new study was published online in Neurology.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos